KTKathryn J. Timko

Kathryn J. Timko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kathryn J. Timko has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Corticosteroid Administration Enhances the Glycemic, Insulinemic, and Incretin Responses to a High-Protein Mixed Meal in Adult Horses

    by Allison T. Palmer, Mauria R. Watts, Kathryn J. Timko, Erin F. Pinnell, Katelyn A. Keefer, Olivia Gorman, Laura D. Hostnik, Teresa A. Burns

    Background: Corticosteroids are used routinely in horses and induce insulin dysregulation (ID). Nutrition is important for ID management and includes low nonstructural carbohydrate (NSC) diets and, often, high-protein ration balancers (RB). Insulin and incretin secretion increase after high-protein meals; corticosteroids may influence these effects. Hypothesis: A high-protein mixed meal will induce hyperinsulinemia and increased concentrations of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) in horses with ID; dexamethasone (DEX) will amplify this effect. Animals: Five horses with naturally occurring ID. Methods: Horses underwent an IV glucose tolerance test and a feed challenge test (FCT; 1 kg RB). Tests were repeated after DEX administration (0.08 mg/kg PO q24h, 7 days). Insulin, glucose, and incretin dynamics were compared pre- and post-DEX. Results: Corticosteroids exacerbated post-prandial hyperinsulinemia and hyperglycemia after a high-protein meal. The FCT area under the curve for insulin (AUCINS) after DEX was significantly higher than baseline (558 ± 182 μIU/mL × min vs. 257 ± 93.9 μIU/mL × min; p = 0.03). The maximum concentration of GIP (CmaxGIP) after DEX (381 ± 70.6 pg/mL) was significantly higher than baseline (262 ± 13.7 pg/mL; p = 0.013). The AUC for GLP-1 (AUCGLP-1; 31.1 ± 15.2 vs. 50 ± 20.2 pg/mL; p = 0.19) and the Cmax of GLP-1 (CmaxGLP-1; 39.1 ± 25.3 vs. 29.6 ± 12.2 pg/mL; p = 0.32) did not differ between DEX and baseline. Conclusions and Clinical Importance: Metabolic responses to a high-protein mixed meal were exacerbated by corticosteroids. Horses receiving corticosteroids had larger GIP responses, which may enhance post-prandial hyperinsulinemia.


  • Open Access

    Effect of 5′-adenosine monophosphate-activated protein kinase agonists on insulin and glucose dynamics in experimentally induced insulin dysregulation in horses

    by Erin F. Pinnell, Laura D. Hostnik, Mauria R. Watts, Kathryn J. Timko, Allison A. Thriffiley, Mercedes R. Stover, Lauren E. Koenig, Olivia M. Gorman, Ramiro E. Toribio, Teresa A. Burns

    Background: 5′-adenosine monophosphate-activated protein kinase (AMPK) agonists, particularly resveratrol (RES), have not been extensively evaluated for their effect on insulin dysregulation (ID) in horses. Objectives: Evaluate the effects of treatment with RES (10 mg/kg PO q12h), metformin (MET; 30 mg/kg PO q12h), and aspirin (ASP; 20 mg/kg PO q24h) on experimentally induced ID. Animals: Thirty-three healthy, adult, light-breed horses. Methods: Unblinded, placebo-controlled, experimental trial evaluating effects of AMPK agonists (RES, MET, and ASP) on experimentally induced ID. Horses were randomly assigned to a treatment group (RES, MET/ASP, RES/ASP, RES/MET/ASP, or placebo [CON]) after induction of ID with dexamethasone (0.08 mg/kg PO q24h for 7 days). Frequently sampled insulin-modified IV glucose tolerance tests (FSIGTT) and oral sugar tests (OST) were performed at baseline, 7 days after ID, and ID plus 7 days of treatment. Minimal model and OST variables were compared between (1-way ANOVA) and within (1-way ANOVA for repeated measures) groups over time to determine effects of treatment on ID. Results: Administration of dexamethasone for 14 days resulted in significantly altered insulin and glucose dynamics (SI, DI, basal [glucose], and [insulin]) and produced clinical signs of laminitis in 5 out of 33 (15%) of horses included in the study. Combination therapy with RES, MET, and ASP did not significantly improve insulin and glucose dynamics in horses with experimentally induced ID. Conclusions and Clinical Importance: Metabolic testing before glucocorticoid administration should be considered in horses with clinical signs of metabolic syndrome.